Successful establishment of lenvatinib-resistant PLC/PRF/5 cells was confirmed by the observation that lenvatinib failed to suppress tumor growth, accompanied with high CDK6 expression (Supplementary Fig. 11). Here, CDK6 is linked to neoplasm.